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Abstract
Background: Many of the current standard therapies employed for the management of primary malignant brain cancers are
largely viewed as palliative, ultimately because these conventional strategies have been shown, in many instances, to
decrease patient quality of life while only offering a modest increase in the length of survival. We propose that caloric
restriction (CR) is an alternative metabolic therapy for brain cancer management that will not only improve survival but also
reduce the morbidity associated with disease. Although we have shown that CR manages tumor growth and improves
survival through multiple molecular and biochemical mechanisms, little information is known about the role that CR plays in
modulating inflammation in brain tumor tissue.
Methodology/Principal Findings: Phosphorylation and activation of nuclear factor kB (NF-kB) results in the transactivation
of many genes including those encoding cycloxygenase-2 (COX-2) and allograft inflammatory factor-1 (AIF-1), both of which
are proteins that are primarily expressed by inflammatory and malignant cancer cells. COX-2 has been shown to enhance
inflammation and promote tumor cell survival in both in vitro and in vivo studies. In the current report, we demonstrate that
the p65 subunit of NF-kB was expressed constitutively in the CT-2A tumor compared with contra-lateral normal brain tissue,
and we also show that CR reduces (i) the phosphorylation and degree of transcriptional activation of the NF-kB-dependent
genes COX-2 and AIF-1 in tumor tissue, as well as (ii) the expression of proinflammatory markers lying downstream of NF-kB
in the CT-2A malignant mouse astrocytoma, [e.g. macrophage inflammatory protein-2 (MIP-2)]. On the whole, our date
indicate that the NF-kB inflammatory pathway is constitutively activated in the CT-2A astrocytoma and that CR targets this
pathway and inflammation.
Conclusion: CR could be effective in reducing malignant brain tumor growth in part by inhibiting inflammation in the
primary brain tumor.
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Introduction
Malignant astrocytomas are the most common primary
brain tumor and represent a leading cause of cancer-related
d e a t hi nc h i l d r e na n dt h ee l d e r l y[ 1 , 2 , 3 , 4 ] .L o n g - t e r m
progression-free survival is poor for most patients with malig-
nant brain tumors [5,6]. The inability to effectively manage
astrocytomas has been due in part to the unique anatomical
and metabolic environment of the brain that prevents the
complete resection of tumor tissue and impedes the delivery of
therapeutic agents.
The highly invasive and inflammatory phenotype of malignant
astrocytoma cells as well as that of tumor associated lymphocytes
and macrophages contribute to a breakdown of the blood brain
barrier [7,8,9,10,11], mediated, in part, by the release of
interleukins and cytokines that increase vascular permeability,
and thus facilitate the transudation of plasma into the interstitium
followed by the development of cerebral edema and increased
intracranial pressure [7,8,9,12,13].
Although the glucocorticoid, dexamethasone, is currently the
standard drug of choice for attempting to mitigate tumor-
associated inflammation and edema [14,15,16] the drug has been
found to produce a significant number of adverse effects including
hyperglycemia—which may ultimately facilitate tumor growth,
gastritis, gastrointestinal bleeding, weight-gain, Cushing’s syn-
drome, and immuno-suppression [15] [16] [17,18]. In light of the
aforementioned, less toxic therapies are necessary to manage peri-
tumoral inflammation and the sequelae of tumor cell infiltration
and accompanying cerebral edema in patients with malignant
astrocytoma.
To our knowledge, few studies exist that describe an alternative,
non-steroid based approach for the management of the inflam-
matory phenotype of most malignant astrocytoma. Caloric
restriction (CR), the total reduction in dietary food intake without
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micro-nutrients for short term study, has long been proposed as an
alternative therapeutic approach for managing malignant brain
tumor growth, delaying disease progression, and in increasing
long-term survival in mice bearing orthotopically implanted
tumors [19,20,21] [22,23]. In addition to multiple reports
suggesting that CR is a broad-spectrum inhibitor of many
metabolic processes and signaling cascades in experimental brain
tumors, CR has also been shown to improve the health and
increase the longevity of mice bearing a malignant astrocytoma
[19,20,21] [22,23].
NF-kB signaling and activation is associated with cellular
proliferation, apoptosis, angiogenesis and inflammation in brain
and other cancers [24,25,26,27,28]. NF-kB increases the expres-
sion of a number of anti-apoptotic molecules, while also increasing
the expression of angiogenic factors and pro-inflammatory
mediators [26,27,29,30,31]. Five proteins comprise the mamma-
lian NF-kB family [32,33]. RelA (p65), RelB, c-Rel have a
transactivation domain in their C-termini. In contrast, NF-kB1
and 2 proteins are synthesized as large precursors, p105 and p100,
which generate the mature p50 and p52 subunits, respectively.
The expression of constitutively activated RelA/NF-kBi s
associated with malignancy in astrocytomas and plays a critical
role in tumor invasion [24,34]. In an inactivated state, NF-kBi s
located in the cytosol complexed with the inhibitory protein IkBa
[35,36]. A variety of growth factor signals can activate IkB kinase.
This induces Ikba phosphorylation, ubiquitination, and proteo-
some degradation. Activated NF-kB translocates to the nucleus,
binds to DNA, and then activates a number of pro-inflammatory
molecules like COX-2, TNF-a, IL-6, IL-8, MMP-9 [26,37].
COX-2 expression plays a key role in the development of edema
in brain tumors [9,38].
Despite the anti-inflammatory effects of CR on aging and other
neurodegenerative disorders, little is known about the effects of
CR on brain cancer inflammation. A recent report showed that
CR has an anti-oxidative and anti-inflammatory vasoprotective
effects in aging rats [39]. In this report, life long CR significantly
improved endothelial function, attenuated vascular ROS produc-
tion, inhibited NF-kB activity, and down regulated inflammatory
genes. Another recent study on renal ischemia perfusion injury
model in mice clearly showed that short term dietary restriction
and fasting can protect tissue from ischemic damage associated
with improved insulin sensitivity, reduced expression of markers of
inflammation, and insulin like growth factor 1 signaling [40].
The association between chronic systemic inflammation,
obesity, and cancer is well established [41,42,43,44,45]. In obese
patients, CR decreases levels of pro-inflammatory molecules, while
increasing levels of anti-inflammatory molecules [46,47,48,49].
Circulating leptin levels were lower in obese asthma patients under
alternate day fasting than in patients under continuous ad libitum
food intake [48]. Leptin has been shown to exert pro-inflamma-
tory actions and it is possible that anti-inflammatory effects of CR
in obese patients could be through reduced leptin level [45,48].
In addition to inflammatory neoplastic cells, glioma associated
inflammatory cells also influence peri-tumoral edema formation
and tumor progression [7,8,9,50]. Tumor associated macrophages
is a major connection between cancer and inflammation [11].
Constitutive NF-kB activation in cancer cells is often increased by
microenvironment signals like pro-inflammatory cytokines ex-
pressed by infiltrating leukocytes [10,11]. We showed that CR
reduced both number and expression of CD68 positive cells and
protein in CT-2A tumors. Kari and co-worker showed that CR
suppressed the production of inflammatory cytokines from alveolar
macrophages challenge with a gram-positive bacteria and
increased its phagocytic activity [51]. Hursting and co-workers
recently showed that CR could reduce macrophage infiltration
into MC38 colon carcinoma [52].
In this study, we investigated for the first time the effects of CR
on inflammatory biomarkers in the CT-2A malignant mouse
astrocytoma. A moderate 30% CR significantly reduced COX-2
and AIF-1 expression in the CT-2A astrocytoma. In addition, NF-
kB p65 phosphorylation, DNA binding was significantly less in
CT-2A tumors from mice receiving CR than in mice receiving the
standard chow diet unrestricted. Moreover, CR reduced MIP-2
expression in tumor tissues. Lastly, CR reduced the number of
macrophages in the CT-2A tumor. Our results indicate that CR
has anti-inflammatory action against the CT-2A mouse astrocy-
toma and suggest that CR would likely be an effective anti-
inflammatory dietary intervention against human brain tumors.
Materials and Methods
Animals and Experimental Astrocytoma
Mice of the C57BL/6J (B6) strain were obtained from the
Jackson laboratory (Bar Harbor, ME, USA) and were propagated
in the Boston College Animal Care Facility as previously described
[53]. Adult male mice (8–10 weeks of age) were used for the studies
and were housed individually in plastic cages with filter tops
containing Sani-chip bedding (P.J. Murphey Forest Products
Corp., Montville, NJ, USA). Cotton nesting pads were provided
for all mice for warmth and the room temperature was maintained
at 2261uC on a 12 h light/dark cycle. The procedures for animal
use were in strict adherence to the NIH Guide for the Care and
Use of Laboratory Animals and were approved by the Institutional
Animal Care Committee at Boston College. The syngeneic
malignant mouse astrocytoma, CT-2A, was originally produced
in our laboratory by implantation of a chemical carcinogen, 20-
methylcholanthrene, into the cerebral cortex of B6 mice according
to the procedure described by Zimmerman [54]. The CT-2A
tumor is histologically classified as a poorly differentiated highly
malignant astrocytoma that grows orthotopically as a soft,
noncohesive, and highly vascularized mass, that also exhibits
many molecular and biochemical similarities with high grade
gliomas in humans [54],[55].
Antibodies and Reagents
Antibodies were obtained from Cell Signaling (Beverly, MA,
USA) against phospho-NF-kB (p65) (S-536), total NF-kB( p 6 5 ) ,
phospho-IkB (T-19/S-23), total IkB, COX-2, TNF-a, AIF-1, MIP-
2, and for the lysis buffer. CD68 (M-20), Anti-b-actin, goat anti-
rabbit, IgG-HRP, and goat anti-mouse IgG-HRP antibodies were
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). Histone 2B antibody was obtained from Imgenex (Cam-
bridge, MA, USA). The Nuclear extraction kit and the electropho-
retic mobility shift assay (EMSA) kit were purchased from Panomics
(Fremont, CA). 2,2,2-tribromoethanol and tert-amyl alcohol were
obtained from Sigma (St. Louis, MO, USA). The StanBio
Enzymatic Glucose Assay kit (1075-102) was obtained from StanBio
Laboratories (Boerne, TX, USA). The DC Protein Assay kit was
purchased from Bio-Rad (Hercules, CA, USA).
Intracerebral (i.c.) Tumor Implantation
The CT-2A tumor is maintained in vivo by implanting an
,1m m
3 fragment of tumor tissue into the right cerebral cortex of
B6 mice using a trocar (size 1 mm
3 diameter) as we described
previously [56]. Briefly, mice were anesthetized with 2,2,2-
tribromoethanol, i.p., and their heads were shaved and swabbed
with 70% ethanol under sterile conditions. Small tumor fragments
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3, estimated using 1 mm61 mm grid) from a donor
mouse were implanted into the right cerebral cortex of
anesthetized recipient mice. All of the mice recovered from the
surgical procedure and were returned to their cages when fully
active. Initiation of tumors from intact tumor fragments is
preferable to initiation from cultured cells because the fragments
contain an already established microenvironment that facilitates
rapid tumor growth [22,56].
Dietary regimens, body weight, and food intake
measurements
All mice received PROLAB RMH 3000 chow diet (Lab Diet,
Richmond, IN, USA) prior to the initiation of the study. This
regimen contained a balance of mouse nutritional ingredients and
delivers 4.1 kcal g-1 gross energy, where fat, carbohydrate,
protein, and fiber comprised 55, 520, 225, and 45 g kg
21 of the
diet, respectively. Mice were separated into individual cages 1 wk
before tumor implantation, during which time body weight and
food intake measurements were recorded every 3 days to gather
baseline information as we described [19,20,21]. All tumor-
bearing mice were fed ad libitum (AL) for the first 48 hrs after
tumor implantation and were then randomly assigned to one of
two diet groups that received rodent chow in either unrestricted
(AL; n=10; 5 each for growth and tissue analysis) or calorically
restricted (CR; n=10) amounts. The two groups were matched for
body weight (,28.0 g) prior to the initiation of CR. The CR
group received a feeding regimen of 30% less or 70% of food AL
mice daily consume. Body weight and food intake of all mice was
recorded daily (1:00PM – 3:00PM). The food intake for the AL-fed
mice was determined daily by subtracting the weight of the food
pellets remaining in the food hopper from the amount that was
provided 24 hrs earlier. New food was provided every four days
for AL mice. For mice in the CR group, food pellets were dropped
directly into each cage daily for easy access. Water was provided ad
libitum for all mice. The study was continued for 15 days after
tumor implantation until the AL mice started decreasing their
body weight and food intake.
Tissue processing and blood collection
All food was removed from the cages 3 hours before the blood
collection. Mice were anesthetized with isoflurane (Halocarbon
Laboratories, River Edge, NJ, USA) and euthanized by exsangui-
nation, involving collection of blood from the retro-orbital sinus
into heparinized Eppendorf tubes using a glass capillary tube.
Whole blood was centrifuged at 3,0006g for 10 min, the plasma
supernatant was collected, and aliquots (two fractions per aliquot
of plasma supernatant) were stored at 280uC prior to analysis.
Tumors were dissected from normal appearing brain parenchyma
and immediately placed on dry ice to reduce tissue degradation.
Residual normal appearing contra-lateral (left) brain tissue was
also removed and frozen on dry ice [19,22]. For immunohisto-
chemistry tumor and brain tissues were fixed in formalin. If
necessary, mice were euthanized prior to the completion of the
study when brain tumors became peripherally ulcerated or when
mice showed morbidity as defined by our Institutional Animal
Care and Use Committee guidelines.
Measurement of plasma glucose and plasma b-OHB
Plasma glucose and b-OHB concentrations were measured
spectrophotometrically using the StanBioH Enzymatic Glucose Assay
(1075-102) (StanBio Laboratory, Boerne, TX, USA) and a modifi-
cation of the Williamson et al., enzymatic procedure [57], respectively.
For blood ketone body analysis, we measured only b-OHB levels
because this is the major blood ketone body in plasma [58].
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear and cytosolic extracts from AL and CR tumor tissue
were prepared as described in the manufacturer’s protocol
(Nuclear extraction kit, Panomics, Fremont, CA). Protein
concentrations were determined using the BioRad DC assay.
5 mg of nuclear extracts from tissues were mixed with biotin
labeled NF-kB probes (EMSA kit; Panomics) and incubated at
15uC for 30 min in a thermal cycler. For control assays, excess
unlabeled double-stranded DNA was added in the incubation
mixture for DNA protein binding competition assay during the
hybridization period. The mixture was then loaded on a 6% non-
denaturing polyacrylamide gel and electrophoresed at 120 V in
0.5% Tris borate EDTA onto a nylon membrane at 300 mA for
30 min. After transfer, the sample was fixed on the membrane by
UV crosslinking for 3 min. The bands were visualized after
exposure to chemiluminescence film based on the streptavidin
horseradish peroxidase (HRP) reaction.
Western Blot Analysis of phospho-NF-kB (p65) (S-536),
total NF-kB (p65), phospho-IkB (T-19/S-23), total IkB,
COX-2, TNF-a, AIF-1, and MIP-2 in CT-2A under AL-fed
and CR- fed conditions
CT-2A tumor and contralateral normal brain tissue were
homogenized in ice-cold lysis buffer (Cell Signaling Technology,
Beverly, MA, USA) containing 20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton,
2.5 mM NaPPi, 1 mM a-glycerophosphate, 1 mM Na3PO4,
1 mg/mL leupeptin and 1 mM phenylmethylsufonyl fluoride.
Lysates were transferred to 1.7 mL Eppendorf tubes, mixed on a
rocker for 1 h at 4uC, and then centrifuged at 8,1006g for 20 min.
Supernatants were collected and protein concentrations were
estimated using the Bio-Rad DC protein assay (Bio-Rad, Hercules,
CA). Approximately 10–40 mg of total protein from each tissue
sample were denatured with SDS-PAGE sample buffer [63 mM
Tris-HCl (pH 6.8), 10% glycerol, 2% SDS, 0.0025% bromophe-
nol blue, and 5% 2-mercaptoethanol] and were resolved by SDS-
PAGE on 4–12% Bis-Tris gels (Invitrogen). Proteins were
transferred to a polyvinyl difluoride (PVDF) immobilon TM-P
membrane (Millipore) overnight at 4uC and blocked in either 5%
non-fat powdered milk or 5% BSA in Tris-buffered saline with
Tween 20 (pH 7.6) for 1–3 hr at room temperature. Membranes
were probed with primary antibodies overnight at 4uC with gentle
shaking. The blots were then incubated with the appropriate
secondary antibody for 1 hr at room temperature (,22uC), and
bands were visualized with enhanced chemiluminescence (Pierce,
Rockford, IL, USA). Each membrane was stripped and reprobed
for b-actin as an internal loading control, and the ratio of the
indicated protein to b-actin was analyzed by scanning densitom-
etry (FluorChem 8900 Software; Alpha Innotech Co., San
Leandro, CA).
Aliquots of nuclear (for NFkB (p65) and cytoplasmic protein
fraction (15 mg) were loaded onto 12% SDS-polyacrylamide gels
for electrophoresis. Following transfer of the protein loaded SDS
gel onto polyvinyl difluoride (PVDF) membrane and blocking in
5% nonfat drymilk pIkB (1:2000), pNF-kB (1:3000), COX-2
(1:3000), AIF-1 (1:1000), MIP-2 (1:1000) and actin (1: 4000) were
detected with primary antibodies followed by horseradish
peroxidase conjugated secondary antibodies (1: 6000). Detection
was performed using chemiluminescence (ECL Western Blotting
analysis system; Amersham Bioscience) [22].
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18085Enzyme Linked Immunosorbent Assay (ELISA) for MIP-2
Concentrations of MIP-2 in the tumor lysates and in plasma
were determined by ELISA using commercially available kit
(R&D, Mouse MIP-2). Recombinant mouse MIP-2 in a buffered
protein base was used as a positive control and standards as
supplied in the kit. MIP-2 concentrations were measured based on
protein concentration in lysates and plasma.
Immunohistochemistry for NF-kB and CD-68 staining
Immunohistochemistry was performed in paraffinized tissue
sections using methods as we previously described [19,20]. Briefly,
after deparaffinization the tissue sections analyzed for CD68 and
NF-kB were placed in 10 mM sodium citrate buffer, pH 6.0, at
95uC for 30 min. For NF-kB antigen unmasking tissues were
digested with trypsin at 37uC for 30 minutes. The sections were
quenched with 0.3% H2O2 methanol for 30 min and then blocked
with10%normalgoatseruminPBS.The sectionswerethentreated
with CD-68 (1:50) or NF-kB (1:100) (SantaCruz Biotechnology,
Santa Cruz, CA) for overnight incubation at 4uC. The sections were
treated with secondary antibody for 30 minutes at room temp. The
sections were next treated with avidin biotin complex, followed by a
DAB substrate stain according to the manufacturer’s directions
(Vectastain Elite ABC kit; Vector, Burlingame, CA). The sections
were rinsed three times with PBS and counterstained with
hematoxylin and mounted. A corresponding tissue section without
primary antibody served as the negative control.
Statistical Analysis
Body weight, food intake, tumor growth, and plasma metabolite
levels were analyzed by two-tailed t-test to calculate a pair-wise
comparison among the AL and CR groups (SPSS 14.0, Chicago,
IL). In each figure, error bars are mean 6 S.E.M. Western blot
and EMSA analyses represent semi-quantitative estimates of the
amount of the indicated protein normalized to the appropriate
corresponding loading control, or protein bound to marker DNA
promoter that is present in a tissue extract. The former was taken
into account in the statistical evaluation of the data.
Results
Constitutive Expression and phosphorylation of NF-kB
(p65) in the CT-2A astrocytoma and in contra-lateral
normal brain as determined by Western blot analysis
Western blot analysis was performed on whole lysate of CT-2A
tumor and contra-lateral normal brain to examine the constitutive
expression of total NF-kB (p65) in tumors. 1 and 4 mg of total protein
from each of tumor and normal brain whole tissue lysate was loaded
in the gel. Beta actin was used as a loading control. The results show
that CT-2A tumor has constitutive expression of NF-kB (p65) when
compared with normal brain (Fig. 1A). We showed that phosphor-
ylated NF-kB (p65) (S-536) was significantly higher in the nuclear
extract of CT-2A astrocytoma compared with that of normal brain
(Fig. 1B). Histone was used as a nuclear loading control. The ratio of
phosphorylated NF-kB to histone was significantly greater in CT-2A
tumor than in normal brain. Overall the results show that both
expression and activation of NF-kB (p65) (S-536) was significantly
greater in the CT-2A astrocytoma compared with that of contra-
lateral normal brain (fig. 1 A and B). These data are consistent with
recent evidence that NF-kB (p65) is constitutively overexpressed and
phosphorylated in malignant astrocytomas, and that expression levels
were significantly low in normal brain tissue [59]. We showed that
NF-kB activation level in CT-2A cells is similar in presence or
absence of TNFa whereas in control mouse astrocytes 10 ng/ml
TNFa is necessary to significantly phosphorylate NF-kBa ts e r - 5 3 6
(fig.1C). These findings suggest that NF-kBi sp r e s e n ti nb o t hm o u s e
astrocytes and CT-2A cells but it is constitutively activated in CT-2A
cells but not in astrocytes. We also showed that strong immunostain-
ing of NF-kB in CT-2A tumors whereas normal brain has les and
weak NF-kB positive stained cells (fig. 1D). These results confirm
that significantly stronger expression of NF-kB in both CT-2A tumor
and cells compared to normal brain or mouse astrocytes.
CR reduces intracerebral tumor growth, bodyweight, and
plasma glucose and increases b-hydroxybutyrate levels
in CT-2A-bearing mice
CT-2A tumor weight was about 65% less in the CR group than
in the AL group (p,0.01) (Fig. 2A). This is consistent with our
previous findings on influence of CR on CT-2A tumor growth
[19,20]. As we previously described tumors were implanted i.c. on
day 0. All tumor-bearing mice were fed ad libitum (AL) for the first
48 hrs after tumor implantation and were then randomly assigned
to one of two diet groups that received rodent chow in either
unrestricted (AL; n=4) or calorically restricted (CR; n=5)
amounts. The two groups were matched for body weight
(,28.0 g) prior to the initiation of CR. The CR group received
a feeding regimen of 30% less or 70% of AL mice daily
consumption. All mice were sacrificed 14–15 days after tumor
implantation when the AL mice started decreasing body weight
and food intake. Body weight of CR animals was significantly
reduced by 30% compared to AL mice (Fig. 2B). Furthermore,
CR significantly reduced plasma glucose levels by 63% (Fig. 2C)
and elevated ketone body levels by 114% (fig. 2D). These finding,
viewed, together consistent with prior reports that moderate CR
can reduce intracerebral tumor growth in CT-2A-bearing mice,
and associated with reduced circulating glucose levels together
with elevated ketone body levels [23,60]. Moreover, these data
support prior studies suggesting that reduced glucose and
increased ketone body levels are primary markers for caloric
restriction [23,60].
Influence of CR on nuclear expression of phosphorylated
NF-kB (p65), cytosolic expression of phosphorylated IkB,
total IkB, and on DNA promoter binding activity of
activated NF-kB in the CT-2A astrocytoma
We showed that NF-kB overexpression is associated with
activation of NF-kB (p65) in CT-2A astrocytoma. Since the
phosphorylation and translocation of p65 subunit of NF-kBf r o m
cytosol to nucleus is the major component in NF-kB activation,
we determined the effect of CR on activation of p65. In addition
we determined the phosphorylation state of IkB, which a direct
inhibitor of NF-kB activation and translocation to the nucleus
where it can subsequently go on to transactivate proinflammatory
gene products. More specifically, activation of the NF-kBi s
initiated by the signal-induced degradation of IkBp r o t e i n s .
Activation of enzyme I-kBk i n a s e( I K K )i nt h ec y t o p l a s m
phosphorylates the IkB protein, which results in ubiquitination,
dissociation of IkBa from NF-kB and eventual degradation of
IkBa by the proteosome, resulting in nuclear translocation of
activated NF-kB that can then go on to transactivate target
proinflammatory genes. The results of western blot analysis
illustrate that the expression of phosphorylated NF-kB (in nuclear
tissue extracts) and phosphorylated IkB (in cytosolic tissue
extracts) were significantly reduced in CR CT-2A astrocytoma
(Fig. 3A-B, respectively). The EMSA data showed that CR
reduced the amount of binding of activated NF-kBt oD N A
promoters of target pro-inflammatory genes in nuclear extracts of
Diet and Brain Tumor
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bearing mice (Fig. 3C-D). To confirm whether the DNA binding
activity of NF-kB is specific, cold unlabeled DNA probe was
added to the mixture of labeled probe and nuclear extract of AL
tumor tissues. The cold probe competes with the labeled DNA
probe for binding to the protein. The former reduced or
eliminated the band’s intensity (Fig. 3C, lane 1). These findings,
viewed together, indicate that the CT-2A astrocytoma shows
constitutive expression of NF-kB compared to normal brain
parenchyma, and that CR reduces NF-kB activation and
subsequent DNA binding to target promoters.
Influence of CR on expression of the proinflammatory
effectors downstream of activated NF-kB: COX-2 and AIF-
1 in the CT-2A astrocytoma
In contrast to COX-1 which is constitutively expressed in nearly all
tissues and mediates the synthesis of prostaglandins required for tissue
homeostasis, COX-2 expression is inducible and increases in response
to various stimuli including inflammatory signals, mitogens, cytokines,
and growth factors, as would occur in the presence of infection,
inflammation, and neoplastic processes [61]. Furthermore, COX-2
has been implicated in the growth and progression of human
malignant gliomas [61].COX-2 expression was significantly lessinthe
tumor of CR fed mice than in that in the AL fed mice (Fig. 4A).
Allograft inflammatory factor 1(AIF1) is a protein that encoded by the
AIF1 gene in humans [62]. AIF1, also known as Iba1, is a 17 kDa
protein and calcium-binding molecule involved in cellular activation
and cell cycle progression [63,64]. AIF-1 expression, which has been
established as a pro-inflammatory gene product of active NF-kB, has
been found in various human cells and tissues such as macrophages,
thymus, liver, lung, and subtypes of invasive malignant gliomas
[62,65,66,67]. The results of Western blot analysis illustrate that CR
significantly reduced expression of AIF-1 in total protein lysates of the
CT-2A astrocytoma (Fig. 4A-B). We found that the basal level of
Figure 1. Expression and Phosphorylation of NF-kB (p65) in CT-2A astrocytoma. Western blot analysis of (A) Total protein expression of
NF-kB (p65) in the whole lysates of tumor tissue and normal brain parenchyma. 1 and 4 mg of protein was loaded for each sample of tumor and brain
tissue. (B) Phosphorylated NF-kB (p65) in nuclear extracts of tumor and normal brain tissues. The histogram illustrates the average relative expression
of p-NFkB (p65) (S-536) to histone in nuclear extracts of the indicated tissue. Values are expressed as normalized means 6 S.E.M of 4–5 independent
tissue samples/group for both A and B. The asterisks in indicate that the value is significantly higher in the CT-2A astrocytoma than in contra-lateral
normal brain at ** P,0.01 (Student t-test). Two representative samples are shown for each tissue type. (C) Phosphorylation of NF-kB in CT-2A cells
and control mouse astrocytes in absence and presence of TNFa (10 ng/ml). (D) NF-kB immunostaining in CT-2A tumor and contra-lateral normal
brain tissues. 3 independent mouse brain tumors were analyzed.
doi:10.1371/journal.pone.0018085.g001
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not shown).
Influence of CR on macrophages inflammatory protein 2
(MIP-2) concentration in the CT-2A tumor and in the
plasma
Macrophage inflammatory protein (MIP-2)/CXCL2 is an induc-
ible murine chemokine involved in attraction of polymorphonuclear
granulocytes to site of infection [68]. CXCL2/MIP-2 induction was
observed in macrophages, epithelial cells, vascular endothelial cells,
astrocytes, mast cells and neutrophils [69,70] [71] [72]. Zampetaki et
al observed that NF-kB activation induced MIP-2 gene expression in
murine macrophages under hypoxic conditions [73]. Although few
studies have showed that CR could reduce the MIP-2 production in
inflammatory sites in murine peritonitis [74], no prior studies have
determined if CR is effective in reducing MIP-2 expression levels in
cancer tissue, especially in malignant astrocytoma. To this end,
ELISA was performed on total protein extracts of CT-2A tumors
from AL- and CR-fed brain tumor bearing mice. The results show
that CR significantly reduced the protein expression of MIP-2 in CT-
2A lysates compared with lysates from AL tumor (Fig. 5A); however,
there was not a significant difference in plasma MIP-2 levels between
the two groups (Fig. 5B). We found a significantly less amount of
MIP-2 in the normal brain in ELISA (data not shown).These findings
indicate that CR reduces MIP-2 levels in the CT-2A tumor compared
with tumors from AL-fed tumor-bearing mice. Furthermore, these
local changes in MIP-2 expression were not reflected on a systemic
level, as there was no significant difference in plasma MIP-2 levels in
CT-2A-bearingfromtheAL-andCR-fedgroup(P=0.378)(Fig.5B).
Influence of CR on CD68 expression in the CT-2A tumor
CD68 is a glycosylated transmembrane protein and is
specifically expressed in macrophages [75]. Number of macro-
phages as detected by brown positive CD68 immunostaining is
Figure 2. Influence of CR on tumor growth, body weight, and plasma biomarkers. Tumors were implanted i.c. on day 0. All tumor-bearing
mice were fed ad libitum (AL) for the first 48 hrs after tumor implantation and were then randomly assigned to one of two diet groups that received
rodent chow in either unrestricted (AL; n=4) or calorically restricted (CR; n=5) amounts. The two groups were matched for body weight (,28.0 g)
prior to the initiation of CR. The CR group received a feeding regimen of 30% less or 70% of food of AL mice consume daily. All mice were sacrificed
14–15 days after tumor implantation, as described above in the Materials and Methods section. Final weights of the mice were obtained
immediately prior to sacrifice (B). The asterisk in indicate that the tumor growth (A), body weight (B), and glucose level (C) is significantly reduced and
ketone level (D) is significantly increased in the CR group compared with the AL group at * P,0.05, ** P,0.001 (Student t-test).
doi:10.1371/journal.pone.0018085.g002
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(Fig. 6A). The brown DAB staining intensity is much stronger in
macrophages from AL tumor tissues than that in CR tumor
tissues. The reduction in CD68 positive cells in CR tumor is also
associated with significant reductions in the protein expression of
CD68 in tumor tissues as detected by western blot (Fig. 6B).
These findings indicate that CR reduces the number of infiltrating
macrophages in the brain tumor.
Discussion
We have clearly established the role of CR in reducing
experimental brain tumor growth through its influence on multiple
signaling cascades that differentially influence energy metabolism
in tumor tissue and normal brain parenchyma [20,22] [21]. To
our knowledge no previous studies have examined the role of CR
in modulating the expression of pro-inflammatory markers in the
CT-2A astrocytoma or in other tumors. Our findings suggest that
the anti-tumor effects of CR can be attributed, in part, to an
attenuation of localized or systemic inflammation. The present
study demonstrates that CR reduces signaling through the NF-kB
pathway thus contributing to the anti-inflammatory effects of CR
in managing CT-2A astrocytoma growth. We found that the anti-
inflammatory effects of CR in the CT-2A astrocytoma were
associated with (i) reduced nuclear NF-kB activation and
subsequent DNA binding to promoters of proinflammatory genes,
(ii) reduced COX-2 and AIF-1 expression, (iii) reduced CD68 and
MIP-2 expression.
NF-kB is a master transcription factor for pro-angiogenic and
anti-apoptotic characteristics of human malignant brain tumors
and NF-kB overexpression is a hallmark of GBM [24,76]. We
previously showed that the CT-2A astrocytoma is highly
angiogenic with numerous thrombotic vasculatures [19,20].
Inflammation dependent angiogenesis is known to drive tumor
Figure 3. Influence of CR on NF-kB expression and activation in CT-2A astrocytoma. Nuclear expression of phosphorylated NF-kB (p65)
(A); cytosolic expression of phosphorylated IkB and total lkB (B) as assessed by western blot analysis, DNA promoter binding activity of activated NF-
kB in the CT-2A astrocytoma (C-D) as assessed by EMSA. The histograms illustrate the average relative expression of phosphorylated to total protein
normalized to the indicated loading control in either nuclear or cytoplasmic extracts of the indicated tissue (A-B). Values are expressed as normalized
means 6 S.E.M of 4–5 independent tissue samples/group. The asterisks in indicate that the value is significantly different in the CT-2A astrocytoma
under AL and CR condition at * P,0.05 (Student t-test). Two representative samples are shown for each tissue type. (C) Evaluation of the extent of
DNA proinflammatory gene promoter binging activity by activated NF-kB in nuclear extracts of CT-2A under AL and CR condition. (D) Coned-down
view of the DNA promoter biding activity of activated NF-kB in nuclear extracts of the NF-kB in the CT-2A astrocytoma under AL and CR condition.
The histogram illustrates the average relative expression of activated NF-kB in the indicated tissue. Values are expressed as normalized means 6
S.E.M of 4–5 independent tissue samples/group. The asterisks indicate that the value is significantly different in the CT-2A astrocytoma under AL and
CR condition at * P,0.05 (Student t-test). Two representative samples are shown for each tissue type.
doi:10.1371/journal.pone.0018085.g003
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and cancer cells, surrounding stromal and infiltrating cells also
influence angiogenesis [10]. Persistent angiogenesis driven by
myeloid inflammatory cells is now recognized in cancer progres-
sion [80]. The constitutive expression of NF-kB and together with
over expression of related inflammatory molecules in the CT-2A
astrocytoma indicates a high degree of inflammation. Our data
show that CR significantly reduced the activation of NF-kB and
downstream pro-inflammatory molecules in CT-2A tumor.
Although the molecular mechanisms by which CR reduces NF-
Figure 4. Influence of CR on inflammatory protein expressions in CT-2A astrocytoma. Cyclooxygenase-2 (COX-2) (A) and Allograft
Inflammatory Factor 1 (AIF-1) (B) in cytosolic extracts of the CT-2A astrocytoma. COX-2 and AIF-1 have both been reported to be downstream
proinflammatory gene-product effectors of the activated NF-kB. The histograms illustrate the average relative expression of the indicated protein
normalized to b-actin in CT-2A tumors (A-B). Values are expressed as normalized means 6 S.E.M of 4–5 independent tissue samples/group. The
asterisks indicate that the value is significantly different in the CR tumor than in the AL tumor at * P,0.05, { P,0.001 (Student t-test). Two
representative samples are shown for each tissue type.
doi:10.1371/journal.pone.0018085.g004
Figure 5. Influence of CR on the Macrophage Inflammatory Protein-2 (MIP-2) concentration. MIP-2 concentration in brain tumor lysates
and in the plasma of mice bearing orthotopically implanted CT-2A tumors as assessed by ELISA. The histograms illustrate the average relative
expression of the indicated protein in CT-2A from AL- and CR-fed mice (A). Influence of CR on expression of the indicated protein in the plasma of CT-
2A-bearing mice fed AL or CR (B). All values are expressed as means 6 S.E.M of 4-5 independent tissues or plasma samples/group. ** P,0.01 indicates
that the average MIP-2 level in tumors from the AL-fed group is significantly different from that in tumors from the CR-fed group (Student t-test).
doi:10.1371/journal.pone.0018085.g005
Diet and Brain Tumor
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e18085kB activation remains unclear, the anti-inflammatory effects of CR
are robust. One possible mechanism could involve a CR-induced
reduction of tumor necrosis factor (TNFa), which could suppress
NF-kB activation in CT-2A tumor [39,51]. Tumor associated
macrophages and other immune cells are the major source of
TNFa [81,82,83]. As we found that macrophage specific CD68
positive cells are significantly less in CR tumor than in AL tumor it
is likely that pro-inflammatory cytokines release from macrophage
will be less in the CR tumor tissue microenvironment. An array
analysis of pro-inflammatory cytokines in separated cell population
of brain tumor cells and tumor infiltrating macrophages from both
AL and CR fed mice would better define the influence of CR on
macrophage-induced inflammation.
A significant positive correlation has been found between
glioma grade and the activation status of Akt and NF-kB [84].
Reduction of PTEN expression, as we previously showed in the
CT-2A tumor, could activate NF-kB through the PI3kinase/Akt
pathway [22]. CR induced inhibition of IGF-1/Akt signaling was
recently demonstrated in CT-2A tumor and therefore could be a
plausible mechanism of inhibiting NF-kB activation [22].
Glucose is used as a major fuel for normal brain energy
metabolism, but brain cells can metabolize ketone bodies for
energy when blood glucose levels decrease as in CR [85]. CR is
known to reduce circulating level of glucose and to elevate the
levels of ketone bodies [22,60,86,87]. Recent reports suggest that
ketone based metabolism reduces inflammation in epilepsy and in
other neurodegenerative disorders [88]. We also recently reported
that elevated ketone levels modulated GBM progression in a
patient treated with a calorie restricted KD [89]. Alternate day
caloric restriction in overweight adults with moderate asthma
significantly increased ketone bodies in the serum and reduced
oxidative stress and inflammation with improved pulmonary
function in 8 weeks trial period [48]. In contrast to other studies,
this alternate day caloric restriction diet had no significant effect
on serum glucose and insulin level [48]. Ketone metabolism results
in a decreased production of reactive oxygen species, known to
contribute to inflammation [90] [85]. Further studies will be
needed to determine if elevated ketones or reduced glucose
underlie the anti-inflammatory effects of CR in brain tumors.
NF-kB mediated COX-2 expression is also greater in more
aggressive than in less aggressive gliomas [91]. Tumor associated
microglia in GBM produce high levels of prostaglandin E (PGE),
which could be mediated by the expression of COX-2. [9,92]. A
selective COX-2 inhibitor appears to be as effective as
dexamethasone in prolonging survival in a rat brain tumor model
[38]. We found that COX-2 protein expression in CT-2A
Figure 6. Influence of CR on CD68 expression in CT-2A tumor. Immunohistochemistry staining shows brown CD68 positive (black arrow) cells
at x400 (A). Each section was representative of the entire tumor. All images are produced from digital photograph. The histograms illustrate the
average number of brown cells in the entire tumor section at 4006from 3 independent mouse tumors in each group. *P,0.05 indicates that the
average CD68 positive cells in tumors from the CR-fed group is significantly less from that in tumors from the AL fed groups. (B) 20 mg of tumor
lysates were loaded and incubated with primary CD68 antibody. b-actin was used as loading control. 3 independent samples of each AL and CR
group were used.
doi:10.1371/journal.pone.0018085.g006
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mice. Extensive evidence suggests reduced chronic inflammation
underlies the anti-aging mechanisms of CR. All these studies were
carried out with a long-term CR regimen [93,94]. However, Jung
et al recently found that CR administered for only 10 days could
suppress lipid peroxidase and COX-2 activities in aged rat kidney
[95]. This observation is consistent with our findings that CR for
10 days was able to reduce COX-2 expression in the orthotopic
CT-2A tumor. The reduced COX-2 expression may be associated
with reduced NF-kB activation in CT-2A tumor from CR mice.
Nevertheless, we cannot exclude the possibilities that other
molecules may be involved in this process. However, further
studies are required to establish this mechanistic link in in vivo
tumor model.
AIF1/Iba1 is thought to play an important rolein chronicimmune
inflammatory processes, especially those involving macrophages.
Previous studies indicate that microglia/macrophage specific Iba1
participates with L-fimbrin to influence migration and phagocytosis
[96]. It was not known if CR could reduce the AIF1/Iba1 expression
in brain tumors. Our present findings support the hypothesis that
AIF1 inhibition could be an indirect effect of reduced number of
tumor infiltrating macrophages due to CR in CT-2A tumor. It is also
important to mention that our recently developed highly invasive
VM3 mouse brain tumor cells are of myeloid origin and are highly
positive for AIF1/Iba1 by gene and protein expression [97]. The
VM3 model represents the full spectrum of growth and invasive
characteristics seen in human GBM [98]. Liu et al recently showed
that AIF1 over-expression in a breast cancer cell line enhances the
transcriptional activity of NF-kB [96]. In light of this observation, it is
possible that the CR-induced inhibition of NF-kBe x p r e s s i o n
inhibition could result in part from inhibition of AIF1 protein
expression. Furthermore, the role of AIF1 in regulation of
angiogenesis in certain tumors is evident [99]. The protein encoded
by the AIF1 gene in humans is thought to be involved in the negative
regulation of vascular smooth muscle cell growth, which could
contribute to the anti-inflammatory response to vessel wall trauma.
This observation could explain our recent unpublished results that
CR restores the smooth muscle actin around the leaky vessels in CT-
2A tumor and reduces leakiness and thrombosis.
MIP-2 is a CXC chemokine that is also produced by infiltrating
inflammatory leukocytes like neutrophils or monocytes. Hypoxia
triggers MIP-2 expression in murine macrophages through NF-kB
activation and involves the p42/p44 and the PI3 kinase pathways
[73]. It was also shown that NF-kB contributes to LPS-induced
mouse MIP-2 gene expression in RAW 264.7 cells [100]. Our
findings suggest that CR influences macrophage linked inflamma-
tory molecules like AIF1 and MIP-2 in CT-2A tumors, and
associated with NF-kB transcription in a direct or indirect manner.
In the present study, the inhibitory effect of CR on MIP-2 level in
tumor tissues may be linked with reduced number of infiltrating
cells. However, CR might influence the immune cells within the
tumor tissue to attenuate MIP-2 release in the circulation. This
might explain, in part, the reason for the lack of any significant
differences in MIP-2 level in the plasma of AL and CR mice.
The potential of CR as an alternative approach for brain tumor
management have been extensively discussed [85,89,101,102,103].
CR could be an alternative therapeutic approach that exploits the
differences in energy metabolism between normal brain cells and
brain tumor cells [85]. We also reported that the restricted amount
of high fatlowcarbohydrate diet is equallyeffective inreducing CT-
2A and U87-MG brain tumor growth as total caloric restriction
[23]. Therefore, we suggest, the amount of calories rather than the
type of calories are more effective in managing tumor growth
[23,60,104]. Additionallythe restricted diet could be combined with
specific drugs to further enhance therapeutic efficacy. In conjunc-
tionwith our previous findings, this study not only establish the anti-
inflammatory effects of CR in a brain tumor model, but also
exemplifies the potential efficacy of CR as a broad-spectrum
inhibitor of malignant astrocytomas.
Viewed collectively, our findings show the anti-inflammatory
effects of CR in the CT-2A astrocytoma are associated with
inhibition of the NF-kB pathway and the linked pro-inflammatory
molecules. CR can be considered a powerful dietary intervention
therapy for malignant brain tumors, as CR can simultaneously
target tumor cells, tumor associated macrophages, and endothelial
cells. Since implementation of CR is easy and without any adverse
side effects CR alone or in conjunction with low dose of
chemotherapy may have some preclinical efficacy as a non
invasive therapy with reduced toxicity for malignant brain cancer.
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